...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Differential impact of CD154 costimulation blockade on alloreactive effector and regulatory T cells in murine renal transplant recipients.
【24h】

Differential impact of CD154 costimulation blockade on alloreactive effector and regulatory T cells in murine renal transplant recipients.

机译:CD154协同刺激对鼠肾移植受体同种反应性效应细胞和调节性T细胞的不同影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Although CD154 costimulation blockade prolongs allograft survival in multiple transplantation models, the underlying immunological mechanisms remain to be elucidated. METHODS AND RESULTS: We used a murine orthotopic kidney allograft (KTx) model to analyze the impact of CD154 blockade on trafficking and function of alloreactive T effector versus T regulatory cells. A single dose of MR1 Ab treatment at the time of KTx significantly improved the survival of Balb/c KTx in naive C57BL/6 recipients (mean survival time >100 days vs. 52 days in controls; P<0.005), and improved graft histology, as evidenced by decreased lymphocyte infiltration and preservation of tissue architecture (days 6-8). In the early posttransplant phase, fluorescence-activated cell sorting analysis revealed preferential depression of T effector (CD8+CD25+) and relative enrichment of T-regulatory (CD4+ CD25+ CD152+) cells selectively in KTx. This pattern was further supported by intragraft gene expression analysis, which showed increased FoxP3/Tbet ratio and simultaneously decreased granzyme B/IFN-gamma levels in Ab-treated recipients. Additionally, MR1 Ab selectively up-regulated intragraft CCL17, but suppressed CXCL9/CCL5, in parallel with increased CCR4/CCR8 but unaltered CXCR3 expression. CONCLUSION: These results provide evidence, at both cellular and molecular levels, that CD154 blockade in murine KTx recipients differentially targeted T-effector and T-regulatory cell subsets by regulating intragraft induction of chemokines targeting distinct T-cell subsets.
机译:背景:尽管CD154协同刺激可以延长同种异体移植模型的存活时间,但其潜在的免疫学机制仍有待阐明。方法和结果:我们使用小鼠原位肾脏同种异体移植(KTx)模型来分析CD154阻断对同种反应性T效应子与T调节细胞的运输和功能的影响。 KTx时单剂MR1 Ab治疗显着改善了天真C57BL / 6受体中Balb / c KTx的存活率(平均存活时间> 100天,对照组为52天; P <0.005),并改善了移植物组织学,如减少的淋巴细胞浸润和组织结构的保存所证明(第6-8天)。在移植后的早期阶段,荧光激活的细胞分选分析显示,在KTx中选择性抑制T效应子(CD8 + CD25 +)和相对富集T调节性细胞(CD4 + CD25 + CD152 +)。移植物内部基因表达分析进一步支持了这种模式,该分析表明,Ab处理的受体中FoxP3 / Tbet比例增加,同时颗粒酶B /IFN-γ水平降低。此外,MR1 Ab与CCR4 / CCR8增加但CXCR3表达未改变同时,选择性地上调了移植物内CCL17,但抑制了CXCL9 / CCL5。结论:这些结果提供了在细胞和分子水平上的证据,表明鼠KTx受体中的CD154阻断通过调节针对不同T细胞亚群的趋化因子的移植物内诱导而差异地靶向T细胞和T调节细胞亚群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号